Rodríguez BJL, García VJL, Giral BC, Hernández SD, Jasso GL

Language: Spanish
References: 8
Page: 327-329
PDF size: 54.74 Kb.

ABSTRACT

In 1961, worldwide consternation in response to the thalidomide disaster made clear the need to detect adverse drug reactions at the earliest possible time. This led to the establishment of the WHO International Drug Monitoring Programme with the initial participation of 10 countries. To date, participation has increased to 71 countries. Mexico joined the WHO International Drug Monitoring Programme in 1999; nonetheless, pharma-covigilance in Mexico began in 1989. In fulfillment of what is established in the General Health Law (Ley General de Salud) in its Article 58, fraction V bis, and to its official designation as an Institutional Center, the Mexican Social Security Institute (IMSS) also implemented the program within its system in 1997. This article is the first of a series that endeavors to review the organization, methodology, functions, outcomes, and challenges of the Interna-tional, National, and Institutional Pharmacovigilance Program.

REFERENCES

1. Organización Mundial de la Salud. Vigilancia farmacológica internacional. Función del hospital. Informe de una reunión de la OMS, Ginebra, Suiza: OMS, Serie de Informes Técnicos Núm. 425; 1969.

2. World Health Organization. The Uppsala Moni-toring Centre. Safety monitoring of medicinal products. Guidelines for setting and running a pharmacovigilance centre. Uppsala, Sweden: WHO Collaborating Centre for International Drug Moni-toring; 2000.

3. WHO Collaborating Centre for International Drug Monitoring. Viewpoint Part 1. Uppsala, Sweden: The Uppsala Monitoring Centre; 2002.

4. Boussel P, Bonnemain H, Bové J. History of phar-macy and pharmaceutical industry. Paris, France: Aslepios Press; 1982.

5. Erill S. Avances en las técnicas de detección de reacciones adversas de los medicamentos. En: Laporte J, Salvá JA, editores. Avances en terapéutica 5. Barcelona, España: Salvat Editores; 1974. p. 124-148.

6. Cartwright FF. Disease and history. New York, USA: Barnes and Noble Books; 1991.

7. Lindquist AM. Seeing and observing in interna-tional pharmacovigilance. Uppsala, Sweden: The Uppsala Monitoring Centre; 2003.

8. Becerril MM, Díaz MA, Bondani GA. Introducción a la farmacovigilancia. México: SSa; 1995.